Telix Pharmaceuticals to Present Cancer Trials and Theranostics at EANM Congress

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) will present 20 company-related abstracts at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna, Austria, from October 17-21, 2026. The presentations showcase the company's pipeline, including pivotal therapeutic studies, precision diagnostics, and next-generation theranostic programs.

Key presentations include Phase 3 trials for TLX101-Tx in recurrent glioblastoma (IPAX BrIGHT) and TLX250-Tx in renal cell carcinoma (LUTEON), alongside interim results from the PTherpan-Lu trial for TLX597-Tx in prostate cancer. The company will also share Phase 3 data for TLX591-Px (Illuccix) prostate cancer imaging and real-world experience with TLX250-Px (Zircaix). Telix is also set to present research on its targeted alpha therapies and medical technology advancements.

"Our expansive presence at EANM reflects the breadth and maturity of Telix's pipeline," said Dr. David N. Cade, Telix Group Chief Medical Officer. He noted that 12 abstracts were selected for top-rated oral presentations, signifying strong recognition of the work's quality and clinical relevance. Telix will host a sponsored symposium discussing the future of theranostics in urologic oncology.

Visitors can explore Telix's commercial PSMA-PET imaging agent, Illuccix®, at booth #527. The company will also showcase its theranostic pipeline and medical technologies, including the SENSEI® miniature gamma probe, QDOSE® dosimetry software, and artificial intelligence solutions.